Chemours (CC) Projected to Announce Earnings on Tuesday

Chemours (NYSE:CC) is projected to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Chemours to announce earnings of $0.4964 per share and revenue of $1.6545 billion for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.10. The company had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The business’s revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 EPS. On average, analysts expect Chemours to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Chemours Stock Performance

Shares of CC opened at $16.64 on Monday. The company has a 50-day simple moving average of $19.84 and a 200-day simple moving average of $20.03. The company has a quick ratio of 0.87, a current ratio of 1.82 and a debt-to-equity ratio of 18.98. The company has a market capitalization of $2.50 billion, a PE ratio of -6.30 and a beta of 1.43. Chemours has a 52-week low of $10.44 and a 52-week high of $28.67.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were given a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.1%. The ex-dividend date was Friday, May 15th. Chemours’s dividend payout ratio is presently -13.26%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CC shares. Truist Financial lifted their price target on shares of Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Morgan Stanley raised their price objective on Chemours from $17.00 to $21.00 and gave the company an “equal weight” rating in a research note on Monday, May 11th. Alembic Global Advisors reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Chemours in a report on Wednesday, May 13th. UBS Group boosted their target price on Chemours from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Zacks Research raised Chemours from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.10.

Institutional Trading of Chemours

A number of large investors have recently made changes to their positions in CC. State Street Corp raised its stake in Chemours by 22.7% in the 2nd quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after purchasing an additional 1,131,682 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in Chemours by 13.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 4,796,153 shares of the specialty chemicals company’s stock valued at $75,971,000 after purchasing an additional 580,089 shares in the last quarter. UBS Group AG boosted its stake in shares of Chemours by 0.3% during the 3rd quarter. UBS Group AG now owns 4,754,492 shares of the specialty chemicals company’s stock worth $75,311,000 after purchasing an additional 14,865 shares during the last quarter. Cooper Creek Partners Management LLC acquired a new stake in shares of Chemours during the 3rd quarter worth about $63,103,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Chemours by 36.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,701,294 shares of the specialty chemicals company’s stock worth $43,638,000 after buying an additional 996,012 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.